IL33 and sST2 serum level in systemic sclerosis microvascular involvement

Pellicano, Chiara; Iannazzo, Francesco; Romaggioli, Laura; Rosato, Edoardo

doi:10.1016/j.mvr.2022.104344

Cited by 12 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…73 Another study also revealed increased IL33 and sST2 in systemic sclerosis patients that are associated with microvascular damage. 74 It was reported that serum sST2 and IL-33 were dramatically higher in atrial fibrillation patients than in healthy volunteers. 75 In idiopathic inflammatory myopathies (IIMs), there was a correlation between the levels of sST2 and IL-33 and the clinical symptoms.…”

Section: Role Of Il-33 In Cardiac Diseasementioning

confidence: 97%

Roles of IL-33 in the Pathogenesis of Cardiac Disorders

Jiang,

Jin,

et al. 2023

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Interleukin-33 (IL-33) is a member of the IL-1 cytokine family and is believed to play important roles in different diseases by binding to its specific receptor suppression of tumorigenicity 2 (ST2). In the heart, IL-33 is expressed in different cells including cardiomyocytes, fibroblasts, endothelium, and epithelium. Although many studies have been devoted to investigating the effects of IL-33 on heart diseases, its roles in myocardial injuries remain obscure, and thus further studies are mandatory to unravel the underlying molecular mechanisms. We highlighted the current knowledge of the molecular and cellular characteristics of IL-33 and then summarized its major roles in different myocardial injuries, mainly focusing on infection, heart transplantation, coronary atherosclerosis, myocardial infarction, and diabetic cardiomyopathy. This narrative review will summarize current understanding and insights regarding the implications of IL-33 in cardiac diseases and its diagnostic and therapeutic potential for cardiac disease management.

show abstract

Section: Role Of Il-33 In Cardiac Diseasementioning

confidence: 97%

Roles of IL-33 in the Pathogenesis of Cardiac Disorders

Jiang,

Jin,

et al. 2023

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

show abstract

“…Circulating IL18 levels were found to be significantly higher in SSc patients respect to controls [ 134 , 135 ] and, interestingly, serum levels of IL18-binding protein isoform a (IL18BPa), a soluble decoy receptor for IL18, were also found to be elevated in SSc circulation and to positively correlate with sPAP [ 136 ]. As far as IL33 is concerned, different studies reported a significant increase in its circulating levels in SSc [ 137 , 138 , 139 , 140 , 141 ], particularly in patients with DUs [ 137 , 141 ]. Notably, circulating values of soluble suppression of tumorigenicity 2 (ST2), a member of the IL1R/Toll-like receptor family that IL33 binds to, were also found to be higher in SSc patients and to correlate with diastolic dysfunction, sPAP, DUs, and NVC abnormalities [ 140 , 141 ].…”

Section: Cytokinesmentioning

confidence: 99%

“…As far as IL33 is concerned, different studies reported a significant increase in its circulating levels in SSc [ 137 , 138 , 139 , 140 , 141 ], particularly in patients with DUs [ 137 , 141 ]. Notably, circulating values of soluble suppression of tumorigenicity 2 (ST2), a member of the IL1R/Toll-like receptor family that IL33 binds to, were also found to be higher in SSc patients and to correlate with diastolic dysfunction, sPAP, DUs, and NVC abnormalities [ 140 , 141 ]. In particular, ST2 was increased in SSc patients with diastolic dysfunction and lower in those with elevated sPAP [ 140 ].…”

Section: Cytokinesmentioning

confidence: 99%

“…In particular, ST2 was increased in SSc patients with diastolic dysfunction and lower in those with elevated sPAP [ 140 ]. Moreover, SSc patients showing DUs and a late NVC pattern had higher ST2 levels than those without DUs and presenting an active NVC pattern [ 141 ], with ST2 being associated with the development of new DUs [ 141 ]. Finally, SSc patients without proximal-distal gradient (PDG) at laser speckle contrast analysis had significantly higher ST2 compared to SSc patients with PDG [ 141 ].…”

Section: Cytokinesmentioning

confidence: 99%

See 1 more Smart Citation

Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review

Fioretto

Rosa

Matucci‐Cerinic

et al. 2023

IJMS

View full text Add to dashboard Cite

Systemic sclerosis (SSc, scleroderma) is a multifaceted rare connective tissue disease whose pathogenesis is dominated by immune dysregulation, small vessel vasculopathy, impaired angiogenesis, and both cutaneous and visceral fibrosis. Microvascular impairment represents the initial event of the disease, preceding fibrosis by months or years and accounting for the main disabling and/or life-threatening clinical manifestations, including telangiectasias, pitting scars, periungual microvascular abnormalities (e.g., giant capillaries, hemorrhages, avascular areas, ramified/bushy capillaries) clinically detectable by nailfold videocapillaroscopy, ischemic digital ulcers, pulmonary arterial hypertension, and scleroderma renal crisis. Despite a variety of available treatment options, treatment of SSc-related vascular disease remains problematic, even considering SSc etherogenity and the quite narrow therapeutic window. In this context, plenty of studies have highlighted the great usefulness in clinical practice of vascular biomarkers allowing clinicians to assess the evolution of the pathological process affecting the vessels, as well as to predict the prognosis and the response to therapy. The current narrative review provides an up-to-date overview of the main candidate vascular biomarkers that have been proposed for SSc, focusing on their main reported associations with characteristic clinical vascular features of the disease.

show abstract

“…The exact processes of SSc pathogenesis are not clear. However, the pathogenic processes can be summarized in three main events: the endothelial injury with a consequent microvasculopathy, followed by the autoimmune response and inflammation and finally a diffuse fibrosis of skin and internal organs [1][2][3][4][5][6][7][8][9][10][109][110][111][112][113][114][115][116][117][118]. Several studies confirmed the role of each of these three events and their interaction in SSc pathogenesis.…”

Section: Systemic Sclerosis Pathogenesismentioning

confidence: 99%

Biomarkers in Systemic Sclerosis: An Overview

Di Maggio,

Confalonieri,

Salton

et al. 2023

CIMB

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a complex autoimmune disease characterized by significant fibrosis of the skin and internal organs, with the main involvement of the lungs, kidneys, heart, esophagus, and intestines. SSc is also characterized by macro- and microvascular damage with reduced peripheral blood perfusion. Several studies have reported more than 240 pathways and numerous dysregulation proteins, giving insight into how the field of biomarkers in SSc is still extremely complex and evolving. Antinuclear antibodies (ANA) are present in more than 90% of SSc patients, and anti-centromere and anti-topoisomerase I antibodies are considered classic biomarkers with precise clinical features. Recent studies have reported that trans-forming growth factor β (TGF-β) plays a central role in the fibrotic process. In addition, interferon regulatory factor 5 (IRF5), interleukin receptor-associated kinase-1 (IRAK-1), connective tissue growth factor (CTGF), transducer and activator of transcription signal 4 (STAT4), pyrin-containing domain 1 (NLRP1), as well as genetic factors, including DRB1 alleles, are implicated in SSc damage. Several interleukins (e.g., IL-1, IL-6, IL-10, IL-17, IL-22, and IL-35) and chemokines (e.g., CCL 2, 5, 23, and CXC 9, 10, 16) are elevated in SSc. While adiponectin and maresin 1 are reduced in patients with SSc, biomarkers are important in research but will be increasingly so in the diagnosis and therapeutic approach to SSc. This review aims to present and highlight the various biomarker molecules, pathways, and receptors involved in the pathology of SSc.

show abstract

IL33 and sST2 serum level in systemic sclerosis microvascular involvement

Cited by 12 publications

References 35 publications

Roles of IL-33 in the Pathogenesis of Cardiac Disorders

Roles of IL-33 in the Pathogenesis of Cardiac Disorders

Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review

Biomarkers in Systemic Sclerosis: An Overview

Contact Info

Product

Resources

About